

The efficacy and safety of sarilumab, fully human monoclonal antibody against interleukin 6 receptor, in rheumatoid arthritis: new evidence

Nauchno-Prakticheskaya Revmatologiya

2019; 57, 564-577

DOI: 10.14412/1995-4484-2019-564-57

Citation Report

#	ARTICLE	IF	CITATIONS
1	The effect of olokizumab on rheumatoid arthritis patientâ€™s reported outcomes: results of a double-blind randomized placebo-controlled multicenter phase III trial (CREDO 1). Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 62-69.	1.0	5
2	IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 245-261.	1.0	16
3	Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. Pulmonologiya, 2020, 30, 629-644.	0.8	7
4	Advances in rheumatology at the beginning of the 21st century. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 5-20.	1.0	2
5	Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice. Sovremennaya Revmatologiya, 2022, 16, 21-28.	0.5	0
6	Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 427-437.	1.0	5
7	The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	1.0	6
8	Secondary amyloidosis as a complication of rheumatoid arthritis in a patient with low adherence to treatment. Clinical Medicine and Pharmacology, 2023, 8, 35-40.	0.1	0
9	Dynamics of clinical manifestations and cytokine concentrations in patients with rheumatoid arthritis on olokizumab therapy. Nauchno-Prakticheskaya Revmatologiya, 2023, 61, 475-484.	1.0	0
10	Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab. , 2023, 2, 17.		1